Baldridge, Abigail S. http://orcid.org/0000-0002-1573-0554
Aluka-Omitiran, Kasarachi
Orji, Ikechukwu A.
Shedul, Gabriel L.
Ojo, Tunde M.
Eze, Helen
Shedul, Grace
Ugwuneji, Eugenia N.
Egenti, Nonye B.
Okoli, Rosemary C. B.
Ale, Boni M.
Nwankwo, Ada
Osagie, Samuel
Ye, Jiancheng
Chopra, Aashima
Sanuade, Olutobi A.
Tripathi, Priya
Kandula, Namratha R.
Hirschhorn, Lisa R.
Huffman, Mark D.
Ojji, Dike B.
Funding for this research was provided by:
National Heart, Lung, and Blood Institute (R01HL144708)
Article History
Received: 27 May 2022
Accepted: 10 July 2022
First Online: 2 August 2022
Declarations
:
: Informed consent was waived per the Common Rule. Ethical oversight was provided by the University of Abuja Teaching Hospital Health Research Ethics Committee. The study was also reviewed by the Federal Capital Territory Ethics Committee and Northwestern University Institutional Review Board. The trial was prospectively registered at ExternalRef removed under NCT04158154 on November 8, 2019; ExternalRef removed.
: Not applicable.
: MDH has pending patents for heart failure polypills. George Health Enterprises Pty Ltd (GH) and its subsidiary, George Medicines Pty Ltd, have received investment funds to develop fixed-dose combination products, including combinations of blood pressure-lowering drugs. GH is the social enterprise arm of The George Institute for Global Health.